Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 05 2021
Historique:
received: 15 10 2020
accepted: 20 04 2021
entrez: 21 5 2021
pubmed: 22 5 2021
medline: 30 10 2021
Statut: epublish

Résumé

Low skeletal muscle mass is a well-known prognostic factor for patients treated for a non-small-cell lung cancer by surgery or chemotherapy. However, its impact in patients treated by exclusive radiochemotherapy has never been explored. Our study tries to evaluate the prognostic value of low skeletal muscle mass and other antropometric parameters on this population. Clinical, nutritional and anthropometric date were collected for 93 patients treated by radiochemotherapy for a NSCLC. Anthropometric parameters were measured on the PET/CT by two methods. The first method was a manual segmentation at level L3, used to define Muscle Body Area (MBA

Identifiants

pubmed: 34017035
doi: 10.1038/s41598-021-90187-6
pii: 10.1038/s41598-021-90187-6
pmc: PMC8137692
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10628

Références

J Digit Imaging. 2019 Apr;32(2):241-250
pubmed: 30756268
J Geriatr Oncol. 2018 Nov;9(6):589-593
pubmed: 29779799
Eur Radiol. 2018 Jun;28(6):2455-2463
pubmed: 29318425
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
Clin Cancer Res. 2007 Jun 1;13(11):3264-8
pubmed: 17545532
Eur J Surg Oncol. 2018 Sep;44(9):1419-1424
pubmed: 29685760
BMJ Open. 2014 Jan 02;4(1):e003697
pubmed: 24384894
Br J Nutr. 2004 Jul;92(1):105-11
pubmed: 15230993
J Appl Physiol (1985). 1998 Jul;85(1):115-22
pubmed: 9655763
Acta Oncol. 2015 Mar;54(3):340-8
pubmed: 25225010
Ann Oncol. 2010 Aug;21(8):1594-1598
pubmed: 20089558
Br J Cancer. 2010 Feb 16;102(4):639-44
pubmed: 20087353
Support Care Cancer. 2019 Jul;27(7):2657-2664
pubmed: 30478673
Am J Clin Nutr. 1988 Feb;47(2 Suppl):357-65
pubmed: 3124597
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Tumour Biol. 2016 Sep;37(9):11553-11572
pubmed: 27260630
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Support Care Cancer. 2016 May;24(5):2075-2084
pubmed: 26546456

Auteurs

R Mallet (R)

Department of Radiation Oncology, Centre Henri Becquerel and Rouen University Hospital, & QuantIF-LITIS [EA (Equipe d'Accueil) 4108], Rouen, France.

P Decazes (P)

Department of Nuclear Medicine, Centre Henri Becquerel and Rouen University Hospital, & QuantIF-LITIS [EA (Equipe d'Accueil) 4108-FR CNRS 3638], Faculty of Medicine, University of Rouen, Rouen, France.

R Modzelewski (R)

Department of Nuclear Medicine, Centre Henri Becquerel and Rouen University Hospital, & QuantIF-LITIS [EA (Equipe d'Accueil) 4108-FR CNRS 3638], Faculty of Medicine, University of Rouen, Rouen, France.

J Lequesne (J)

Clinical Research Department, Centre Henri Becquerel, Rouen, France.

P Vera (P)

Department of Nuclear Medicine, Centre Henri Becquerel and Rouen University Hospital, & QuantIF-LITIS [EA (Equipe d'Accueil) 4108-FR CNRS 3638], Faculty of Medicine, University of Rouen, Rouen, France.

B Dubray (B)

Department of Radiation Oncology, Centre Henri Becquerel and Rouen University Hospital, & QuantIF-LITIS [EA (Equipe d'Accueil) 4108], Rouen, France.

S Thureau (S)

Department of Radiation Oncology, Centre Henri Becquerel and Rouen University Hospital, & QuantIF-LITIS [EA (Equipe d'Accueil) 4108], Rouen, France. sebastien.thureau@chb.unicancer.fr.
Department of Nuclear Medicine, Centre Henri Becquerel and Rouen University Hospital, & QuantIF-LITIS [EA (Equipe d'Accueil) 4108-FR CNRS 3638], Faculty of Medicine, University of Rouen, Rouen, France. sebastien.thureau@chb.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH